Cleanslate Medical Group Of Indiana Llc | |
4411 Washington Ave Ste 105 Evansville IN 47714-0805 | |
(812) 213-0304 | |
Not Available |
Full Name | Cleanslate Medical Group Of Indiana Llc |
---|---|
Speciality | Internal Medicine |
Location | 4411 Washington Ave Ste 105, Evansville, Indiana |
Authorized Official Name and Position | Robert Hutchison (CFO) |
Authorized Official Contact | 6154250220 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
Cleanslate Medical Group Of Indiana Llc 8 Cadillac Dr Ste 180 Brentwood TN 37027-5393 Ph: (615) 425-0220 | Cleanslate Medical Group Of Indiana Llc 4411 Washington Ave Ste 105 Evansville IN 47714-0805 Ph: (812) 213-0304 |
NPI Number | 1023464294 |
---|---|
Provider Enumeration Date | 05/06/2016 |
Last Update Date | 03/23/2023 |
Medicare PECOS PAC ID | 4880963909 |
---|---|
Medicare Enrollment ID | O20171023001515 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1023464294 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | (* (Not Available)) | Secondary |
207RA0401X | Internal Medicine - Addiction Medicine | (* (Not Available)) | Primary |
Provider Name | Laura Jean Wicker |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1114981842 PECOS PAC ID: 3971577016 Enrollment ID: I20040824000561 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Ardrienne H Thompson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770633034 PECOS PAC ID: 4587630470 Enrollment ID: I20040902000350 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | James E Meacham |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1548216609 PECOS PAC ID: 6305802745 Enrollment ID: I20041207000752 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Stephanie Ann Reagan |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1083664643 PECOS PAC ID: 5092769091 Enrollment ID: I20050311000233 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Donald S Dunevant |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1821059148 PECOS PAC ID: 3375582265 Enrollment ID: I20050429000497 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Paula A Johnson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1700998440 PECOS PAC ID: 7012957129 Enrollment ID: I20050509000519 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Emma C Wang |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1982647434 PECOS PAC ID: 5890719652 Enrollment ID: I20060119000276 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Randall Cammenga |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1154321107 PECOS PAC ID: 0345255626 Enrollment ID: I20060207000845 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Debora A Nygren |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1487616108 PECOS PAC ID: 9931118726 Enrollment ID: I20060405000618 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | James Anthony Holder |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1053387951 PECOS PAC ID: 3971528217 Enrollment ID: I20060406000610 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Thomas C Kerr |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1154351658 PECOS PAC ID: 4385643469 Enrollment ID: I20061219000338 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Julie Marie Towery |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1902953763 PECOS PAC ID: 8224030754 Enrollment ID: I20070212000582 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | William H Wolfe |
---|---|
Provider Type | Practitioner - Preventive Medicine |
Provider Identifiers | NPI Number: 1083779904 PECOS PAC ID: 5698871945 Enrollment ID: I20070502000311 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Richard L Hon |
---|---|
Provider Type | Practitioner - General Practice |
Provider Identifiers | NPI Number: 1255431813 PECOS PAC ID: 2466426812 Enrollment ID: I20070920000361 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Amy E Walker |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1962592956 PECOS PAC ID: 7012010721 Enrollment ID: I20071023000406 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Jeremy Wilber |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1346457934 PECOS PAC ID: 4082772215 Enrollment ID: I20081016000504 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Barbara A Mickler |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1356454896 PECOS PAC ID: 5890851455 Enrollment ID: I20090305000436 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Autumn C Allgeier |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1568601805 PECOS PAC ID: 9234280546 Enrollment ID: I20090909000375 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Linda D Keith |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1760626402 PECOS PAC ID: 6507906294 Enrollment ID: I20091210000152 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Melissa Jane Truax |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1457465387 PECOS PAC ID: 4183755028 Enrollment ID: I20100622000115 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Rodney Guimont |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1316119837 PECOS PAC ID: 2860523099 Enrollment ID: I20100701000368 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Gregory P Gramelspacher |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1013974088 PECOS PAC ID: 8426181157 Enrollment ID: I20100802000926 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Bridget Ranae Stillions |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1982930889 PECOS PAC ID: 1456546753 Enrollment ID: I20101112000091 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Tara A Mendoza |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1366742488 PECOS PAC ID: 0648455840 Enrollment ID: I20110504000182 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Janie Arington |
---|---|
Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
Provider Identifiers | NPI Number: 1770873739 PECOS PAC ID: 9436329398 Enrollment ID: I20110901000054 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Karen Sue Perry |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1598053985 PECOS PAC ID: 1355511056 Enrollment ID: I20110908001731 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Jack R Lowe |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1093077505 PECOS PAC ID: 1658535844 Enrollment ID: I20120620000317 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Erin Hillers |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1710215686 PECOS PAC ID: 3678742913 Enrollment ID: I20121204000361 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Mckenzie L Hinshaw |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124388103 PECOS PAC ID: 9638311228 Enrollment ID: I20130812000034 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Desma D Allen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1477994291 PECOS PAC ID: 1153557392 Enrollment ID: I20131119000132 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Tara N Weaver |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528483856 PECOS PAC ID: 7911138748 Enrollment ID: I20140320000918 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Angela Geissman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891112769 PECOS PAC ID: 4486568391 Enrollment ID: I20140417000461 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Aileen D Bays |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1831526599 PECOS PAC ID: 6204059637 Enrollment ID: I20140603001499 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Elaine L Burcham |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1003135864 PECOS PAC ID: 6709001217 Enrollment ID: I20140625001149 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Ashley L Grumbine |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1194139956 PECOS PAC ID: 9537385950 Enrollment ID: I20140721001913 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Chadi Saifan |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1740450477 PECOS PAC ID: 1052487923 Enrollment ID: I20140916001233 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Michelle J Wathier |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124436217 PECOS PAC ID: 4486873437 Enrollment ID: I20140924000718 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Donna C Robinson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1235100769 PECOS PAC ID: 6103830302 Enrollment ID: I20141121000166 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Crystal J Woods |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1801102579 PECOS PAC ID: 0143455246 Enrollment ID: I20150116000808 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Rita M Spellman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1619365178 PECOS PAC ID: 4082939202 Enrollment ID: I20150211000675 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kalee M Dunkle |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528498458 PECOS PAC ID: 2466674148 Enrollment ID: I20150326000086 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Jessica R Bleyle |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053703900 PECOS PAC ID: 6709104672 Enrollment ID: I20150406002361 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Samuel A Locoh-donou |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1558700831 PECOS PAC ID: 9739320698 Enrollment ID: I20150612000989 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Jeffrey Coy |
---|---|
Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
Provider Identifiers | NPI Number: 1447494893 PECOS PAC ID: 3274507579 Enrollment ID: I20150626001455 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kumpol Dennison |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1275887770 PECOS PAC ID: 2860706819 Enrollment ID: I20150804004760 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Alison Arnold |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1639546674 PECOS PAC ID: 6800196817 Enrollment ID: I20151124000662 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Julie Teague |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1386033504 PECOS PAC ID: 4688979735 Enrollment ID: I20160226001471 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kristopher A Renzi |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164876447 PECOS PAC ID: 9537451109 Enrollment ID: I20160630001601 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kathy Nobles |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770952582 PECOS PAC ID: 6002109139 Enrollment ID: I20160726002964 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Alexandra M Sanserino |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1184170573 PECOS PAC ID: 8022306752 Enrollment ID: I20161013000706 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Song I Baek |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679020119 PECOS PAC ID: 2163701160 Enrollment ID: I20161115001906 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Perry Minner |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1295123693 PECOS PAC ID: 2466732631 Enrollment ID: I20161205001101 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Claudie Jimenez |
---|---|
Provider Type | Practitioner - Addiction Medicine |
Provider Identifiers | NPI Number: 1396725693 PECOS PAC ID: 3678855798 Enrollment ID: I20170126000224 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Michelle Wallace |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1316471790 PECOS PAC ID: 1355618505 Enrollment ID: I20170518002811 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Patricia A Altman |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1437605193 PECOS PAC ID: 1658648357 Enrollment ID: I20170601000134 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Nora Wilcox |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1023539863 PECOS PAC ID: 3577835370 Enrollment ID: I20170814002114 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Connie A Bronson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1922521608 PECOS PAC ID: 3476827122 Enrollment ID: I20170920000716 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Cynthia E Gannon |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1649366360 PECOS PAC ID: 1658552732 Enrollment ID: I20171108000540 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Brenda Barker |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1336355023 PECOS PAC ID: 7416213178 Enrollment ID: I20171113002533 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Malee Blue |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1730626979 PECOS PAC ID: 2961769609 Enrollment ID: I20171205001040 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Omotayo Temitope Fawibe |
---|---|
Provider Type | Practitioner - Preventive Medicine |
Provider Identifiers | NPI Number: 1851634554 PECOS PAC ID: 0345507950 Enrollment ID: I20171206000631 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Isaiah Cruz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1598217176 PECOS PAC ID: 8426315045 Enrollment ID: I20171206001107 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Brandon Emry |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164938007 PECOS PAC ID: 9032471826 Enrollment ID: I20180314001055 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Joshua R Holley |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1780106096 PECOS PAC ID: 6608138979 Enrollment ID: I20180326002400 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Mary M Brauer |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1902293665 PECOS PAC ID: 2567726177 Enrollment ID: I20180508000902 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Elizabeth Fouch |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528241940 PECOS PAC ID: 7618232679 Enrollment ID: I20180523001087 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kathy Ann Ehler |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1386984789 PECOS PAC ID: 0345541934 Enrollment ID: I20180627001769 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Amelia Horn |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1295196673 PECOS PAC ID: 0143510933 Enrollment ID: I20180727002061 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Shelly Hayes |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770060360 PECOS PAC ID: 0547518698 Enrollment ID: I20180806001382 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Jackie Hawkins |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1760988794 PECOS PAC ID: 9436407558 Enrollment ID: I20180807001519 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Rachael L Moyer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972084317 PECOS PAC ID: 8325390800 Enrollment ID: I20181010003835 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Jennifer Erin Scarberry |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1144717927 PECOS PAC ID: 7214289693 Enrollment ID: I20181012000971 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Thembelani Dube |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1467968040 PECOS PAC ID: 4183976574 Enrollment ID: I20181012001720 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Maydia S Facey |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1851890370 PECOS PAC ID: 1052663440 Enrollment ID: I20181012001881 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Chellee Furbert |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1609358753 PECOS PAC ID: 7214289479 Enrollment ID: I20181016003176 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Heather Ellen Metzger |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1750866430 PECOS PAC ID: 3577816586 Enrollment ID: I20181022000805 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Wayne L Scherbaum |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1912482449 PECOS PAC ID: 2769735158 Enrollment ID: I20181101001451 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kourtney Adon Sterling |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1215412028 PECOS PAC ID: 1759625056 Enrollment ID: I20181127001919 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Varrinder Singh Sandhu |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1598907289 PECOS PAC ID: 7517189277 Enrollment ID: I20181203000302 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kelly J. Edsall |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1780178616 PECOS PAC ID: 6204172687 Enrollment ID: I20190104002469 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Layla Nadir Al-shami |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255483558 PECOS PAC ID: 3173860418 Enrollment ID: I20190124003309 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Jennifer A Solsbury |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1508307224 PECOS PAC ID: 7315215712 Enrollment ID: I20190207002072 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Tessa E Mccoy |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558816751 PECOS PAC ID: 2365730843 Enrollment ID: I20190219000197 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Natalie Claire Hill |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1225501257 PECOS PAC ID: 9436497369 Enrollment ID: I20190219000357 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Patricia Justine Irvin |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1013473297 PECOS PAC ID: 1850630534 Enrollment ID: I20190222002825 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Dreama Michelle Harvey |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1306402383 PECOS PAC ID: 5890021687 Enrollment ID: I20190801000293 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Mame Dillion |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558879056 PECOS PAC ID: 6901136688 Enrollment ID: I20190923002230 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Melissa G Collier |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1003025511 PECOS PAC ID: 9436435633 Enrollment ID: I20190926000665 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Sally Combest |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1790892776 PECOS PAC ID: 0143282673 Enrollment ID: I20190926001630 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Stephanie C Brown |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1639628027 PECOS PAC ID: 1557629680 Enrollment ID: I20191121002570 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Jayme Lantz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891338166 PECOS PAC ID: 8820423577 Enrollment ID: I20200127001835 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Chelsey Wicker |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1386275584 PECOS PAC ID: 8022444025 Enrollment ID: I20200211002605 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kathleen Vanderreyden |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1225668312 PECOS PAC ID: 1557799491 Enrollment ID: I20200307000064 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Alexandra Haggerty |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1881136901 PECOS PAC ID: 6709157027 Enrollment ID: I20200406001172 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Abby R Andress |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255975165 PECOS PAC ID: 7113341140 Enrollment ID: I20200722003455 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kalee Danielle Gerber |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1235740846 PECOS PAC ID: 3678999729 Enrollment ID: I20200819002878 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Katherine E Deer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1407465412 PECOS PAC ID: 6103243860 Enrollment ID: I20200827000265 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Blake Alan Luebbehusen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1154925907 PECOS PAC ID: 7113330259 Enrollment ID: I20210108000781 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Dan Sun |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1295324523 PECOS PAC ID: 1254745722 Enrollment ID: I20210122002582 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Patricia Renae Montgomery |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1316223332 PECOS PAC ID: 7416115266 Enrollment ID: I20210125001408 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kathleen Patricia Keesling |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1841784477 PECOS PAC ID: 2769735521 Enrollment ID: I20210222000991 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Jennifer A Gross |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1295327641 PECOS PAC ID: 6305254863 Enrollment ID: I20210421002537 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Desiree Dawn Bailey |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1568068633 PECOS PAC ID: 9133529399 Enrollment ID: I20210610001039 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Melissa Ann Carter |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053992610 PECOS PAC ID: 6103229620 Enrollment ID: I20210721002929 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Laury Farrell |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891394599 PECOS PAC ID: 7517361645 Enrollment ID: I20210811000992 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Merinda Barbara Bell |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255895199 PECOS PAC ID: 9931438348 Enrollment ID: I20210823001831 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Cerina Cunningham |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255939484 PECOS PAC ID: 9739585613 Enrollment ID: I20210831003398 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Janna Weatherly-brown |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558940692 PECOS PAC ID: 6709274848 Enrollment ID: I20211022001377 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Max M Martin |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1538647409 PECOS PAC ID: 4981092962 Enrollment ID: I20211025000469 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Trang Ca Laube |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1104498773 PECOS PAC ID: 0244629707 Enrollment ID: I20211123000684 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Michaella Johnson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1619553948 PECOS PAC ID: 2961891437 Enrollment ID: I20211123000773 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Bethany Ellen Williams |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1255098000 PECOS PAC ID: 4981095114 Enrollment ID: I20211227000298 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kylie Henderson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1386240463 PECOS PAC ID: 9234520958 Enrollment ID: I20220106001056 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kristin M Millen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1831859354 PECOS PAC ID: 3274926373 Enrollment ID: I20220214002029 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Amanda Rose Barrie |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1497308852 PECOS PAC ID: 1052707700 Enrollment ID: I20220405001487 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Lindsey Carol Roberts |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1336734938 PECOS PAC ID: 8628455243 Enrollment ID: I20220519000701 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Andrea I Mamaril |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1134879042 PECOS PAC ID: 6002294345 Enrollment ID: I20220527001495 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Mark Pardue |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1063033462 PECOS PAC ID: 0345621579 Enrollment ID: I20220720000569 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Melissa Oseguera |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558945378 PECOS PAC ID: 5193125912 Enrollment ID: I20220726001891 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Monica Cecile Lee |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1083353585 PECOS PAC ID: 1850773524 Enrollment ID: I20220728001272 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Beverly R Baldwin |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255926259 PECOS PAC ID: 7416331640 Enrollment ID: I20220907001026 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Katherine Jean Wadsworth |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1508588708 PECOS PAC ID: 1456736701 Enrollment ID: I20220922001359 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Mnjuzi Duncan Nyirenda |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1497414684 PECOS PAC ID: 4082090022 Enrollment ID: I20220929000172 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Courtney R Greer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1518557446 PECOS PAC ID: 5294105839 Enrollment ID: I20221223000423 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Avonne Deanne Dainton |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1477624054 PECOS PAC ID: 1759751217 Enrollment ID: I20221228002035 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Donna K Hollis |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770018525 PECOS PAC ID: 3173800778 Enrollment ID: I20221228002118 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Katie Jo Rood |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1215690623 PECOS PAC ID: 8325409709 Enrollment ID: I20230801004081 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kamalpreet Kaur |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1760995302 PECOS PAC ID: 8820442882 Enrollment ID: I20230925001464 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Mona Elsalaymeh |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1871975359 PECOS PAC ID: 8729438585 Enrollment ID: I20231220002493 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | John A Buonocore |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1992801492 PECOS PAC ID: 6204881170 Enrollment ID: I20240118004271 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Kimberly D Mills |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1740759042 PECOS PAC ID: 1254678782 Enrollment ID: I20240120000297 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Maryann N Van Hook |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1275303679 PECOS PAC ID: 8527411396 Enrollment ID: I20240129000473 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Sheree Itza |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1124516257 PECOS PAC ID: 9133562572 Enrollment ID: I20240213001683 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Alexandra V Killingbeck |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1558879957 PECOS PAC ID: 9436584554 Enrollment ID: I20240216000429 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Provider Name | Angela Fowler |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1962860726 PECOS PAC ID: 9537503271 Enrollment ID: I20240221000963 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.
Patients who want to limit the amount of life support they receive after surgery might have a hard time finding a surgeon willing to do the procedure, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga.
When the central nervous system is injured, oligodendrocyte precursor cells migrate to the lesion and synthesize new myelin sheaths on demyelinated axons. Scientists at the Institute of Molecular Cell Biology at Johannes Gutenberg University Mainz have now discovered that a distinct protein regulates the direction and movement of OPC toward the wound. The transmembrane protein NG2, which is expressed at the surface of OPCs and down-regulated as they mature to myelinating oligodendrocytes, plays an important role in the reaction of OPC to wounding.
Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.
› Verified 6 days ago
Deaconess Clinic I Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4506 1st Ave, Evansville, IN 47710 Phone: 812-428-6161 Fax: 812-421-2883 | |
Deaconess Clinic - Memorial Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 645 Connie Robinson Way, Evansville, IN 47713 Phone: 812-450-8764 Fax: 124-012-1178 | |
Doris Ann Best Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 958 S Kenmore Dr, Suite B, Evansville, IN 47714 Phone: 812-471-8503 | |
Deaconess Clinic Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8600 N Kentucky Ave, Evansville, IN 47725 Phone: 812-426-9565 Fax: 812-426-9572 | |
Bellemeade Family Physicians Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3801 Bellemeade Ave, Suite 200-b, Evansville, IN 47714 Phone: 812-485-3737 | |
Rick Crawford Md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1202 W Buena Vista Rd, Suite 100, Evansville, IN 47710 Phone: 812-480-6698 Fax: 812-437-0037 |